Proteases and protease inhibitors in tumor progression

Advances in Experimental Medicine and Biology

Volumn 425, Issue , 1997, Pages 89-97

  DeClerck, Yves A ^a,b,d   Imren, Suzan ^a   Montgomery, Anthony M P ^c   Mueller, Barbara M ^c   Reisfeld, Ralph A ^c   Laug, Walter E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; CYTOSTATIC AGENT; GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEINASE; PROTEINASE INHIBITOR; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; CANCER INHIBITION; CANCER INVASION; ENZYME INHIBITOR INTERACTION; EXTRACELLULAR MATRIX; HUMAN; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; TUMOR GROWTH;

AMINO ACID SEQUENCE; ANIMALS; CELL DIVISION; DISEASE PROGRESSION; ENDOPEPTIDASES; HUMANS; METALLOENDOPEPTIDASES; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEASE INHIBITORS; SEQUENCE ALIGNMENT; SERINE ENDOPEPTIDASES; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 0031470482     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5391-5_9     Document Type: Article

References (27)

1. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68.
2. Liotta LA, Stetler-Stevenson WG (1990) Metalloproteinases and cancer invasion. Semin Cancer Biol 1: 99-106.
3. Sloane BF (1990) Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol 1: 137-152.
4. DeClerck YA, Laug WE (1993) The role of the extracellular matrix in tumor invasion, metastasis and angiogenesis. In: Teicher BA (ed) Drug Resistance in Oncology. Marcel Dekker, NY, pp 121-163.
5. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA (1993) Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4: 197-250.
6. Chambers AF, Colella R, Denhardt DT, Wilson SM (1992) Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras-rransformed NIH 3T3 cells. Mol Carcinog 5: 238-245.
7. Gabrijelcic D, Svetic B, Spaic D, Skrk J, Budihna M, Dolenc I, Popovic T, Cotic V, Turk V (1992) Cathepsins B, H and L in human breast carcinoma. Eur J Clin Chem Clin Biochem 30: 69-74.
8. Hahnel R, Harvey J, Robbins P, Sterrett G (1993) Cathepsin-D in human breast cancer: correlation with vascular invasion and other clinical and histopathological characteristics. Anticancer Res 13:2131-2135.
9. Brouillet JP, Spyratos F, Hacene K, Fauque J, Freiss G, Dupont F, Maudelonde T, Rochefort H (1993) Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: relative prognostic value versus total cathepsin D. Eur J Cancer 29A: 1248-1251.
10. Castiglioni T, Merino MJ, Elsner B, Lah TT, Sloane BF, Emmert Buck MR (1994) Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer [see comments]. Hum Pathol 25: 857-862.
11. Briozzo P, Morisset M, Capony F, Rougeot C, Rochefort H (1988) In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res 48: 3688-3692.
12. Murphy G, Ward R, Gavrilovic J, Atkinson S (1992) Physiological mechanisms for metalloproteinase activation. Matrix Suppl 1: 224-230.
13. Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H, Terao T (1993) Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. Biochim Biophys Acta 1178: 55-62.
14. Montgomery AM, DeClerck YA, Langley KE, Reisfeld RA, Mueller BM (1993) Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res 53: 693-700.
15. Suzuki K, Lees M, Newlands GFJ, Nagase H, Woolley DE (1995) Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II. Biochem J 305: 301-306.
16. Vassalli JD, Pepper MS (1994) Tumour biology. Membrane proteases in focus [news; comment]. Nature 370: 14-15.
17. Pei D, Weiss SJ (1996) Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 271: 9135-9140.
18. Lim YT, Sugiura Y, Laug WE, Sun B, Garcia A, DeClerck YA (1996) Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. J Cell Physiol 167: 333-340.
19. Pei D, Weiss SJ (1995) Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 375: 244-247.
20. DeClerck YA, Yean TD, Lee Y, Tomich JM, Langley KE (1993) Characterization of the functional domain of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochem J 289: 65-69.
21. Pei D, Majmudar G, Weiss SJ (1994) Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem 269: 25849-25855.
22. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM (1993) Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 59:329-341.
23. Goldberg GI, Marner BL, Grant GA, Eisen AZ, Wilhelm S, He CS (1989) Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci U S A 86: 8207-8211.
24. Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL (1992) Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267: 4583-4591.
25. Strongin AY, Collier I, Bannikov, Marmer BL, Grant GA, Goldberg GI (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase.Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270: 5331-5338.
26. DeClerck YA, Yean TD, Lu HS, Ting J, Langley KE (1991) Inhibition of autoproteolytic activation of interstitial procollagenase by recombinant metalloproteinase inhibitor MI/TIMP-2. J Biol Chem 266: 3893-3899.
27. Kruithof EK, Baker MS, Bunn CL(1995) Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 86: 4007-4024.